Pharma & Biotech News , from our Global Correspondents
Refine Search
Biosimilars
Indian pharmaceutical companies focusing on US generics are building specialty generics pipelines. Price erosion due to increased competition in the USA has hastened Indian drug firms' push towards specialty medicines. The complexity being tapped is the active pharmaceutical ingredient (API) or formulation routes of delivery, a complex dosage form, or where the approval pathway has changed, reports The Pharma Letter’s India correspondent. 30 June 2021
Generics
Russian drugmakers continue to put a pressure on their global rivals operating in the local market, by the launch of production of generics of their original drugs, reports The Pharma Letter’s local correspondent. 29 June 2021
Pharmaceutical
For Dravet Syndrome Awareness Month (June), we explore advances in pharmacological treatments for this rare, drug-resistant epilepsy that is characterized by prolonged seizures and fevers that affect one side of the body.1 28 June 2021
Pharmaceutical
The pharmaceutical industry in Paraguay – comprising of domestic drugmakers and multinationals with a presence in the country – is expected to grow by at least 5% in 2021, writes The Pharma Letter’s Latin American correspondent. 25 June 2021
Generics
Prices for imported pharmaceutical substances are steadily increasing in Russia, which creates serious problems for domestic drugmakers, whose costs have also grown significantly in recent months, according to a recent study, conducted by a local analytics company RNC Pharma, reports The Pharma Letter’s local correspondent. 22 June 2021
Pharmaceutical
The Russian government has changed the requirements for the extension of patents for drugs in the domestic market, according to recent statements, made by some senior state officials and local media, reports The Pharma Letter’s local correspondent. 15 June 2021
Biosimilars
Shares of pharmaceutical companies continued their upward journey at the bourses in India, with the pharma index hitting a new high. Pharma stocks are in focus amid the ongoing COVID-19 pandemic, helping register a strong gain for companies like Aurobindo Pharma, Dr Reddy’s Laboratories and Cadila Healthcare, reports The Pharma Letter’s India correspondent. 15 June 2021
Pharmaceutical
Although drug sales in Russia fell 13% in the first four months of the current year in volume terms to 1.7 billion packages, they grew by 4.8% to 390 billion roubles ($5.4 billion) in terms of value, reports The Pharma Letter’s local correspondent. 15 June 2021
Pharmaceutical
Leading Russian pharmaceutical producers and foreign companies operating in the local market have called on the national government to increase the volume of support for companies that are involved in the development and launch of innovative drugs in the domestic market, The Pharma Letter’s local correspondent reports. 8 June 2021
Pharmaceutical
The research and development of pharmaceuticals is a costly, lengthy, and high-risk venture, spread over four stages of studies: drug discovery, preclinical research, clinical research, and post-marketing studies on safety and effectiveness. The journey of a new drug to the market is estimated to take approximately 10 years and cost billions of US dollars, says Dr Nicola Davies in her exclusive article on the US Food and Drug Administration.1 7 June 2021
Pharmaceutical
The Russian Parliament (State Duma) has finally approved legislation that allows the production of original drugs intended for exports without the permission of a patent holder, according to recent statements by the press-service of the Duma and some local media, reports The Pharma Letter’s local correspondent 1 June 2021
Generics
A sharp rise in the price of raw material of key drugs used in the treatment of COVID-19, as well as other active pharmaceutical ingredients (API) over the last few weeks, has unnerved Indian drug manufacturers. 1 June 2021
Pharmaceutical
A new Russian vaccine against COVID-19 and influenza is being developed at Natsimbio, a subsidiary of the Russian state corporation Rostec, according to recent statements by sources close to the company and local analysts. 25 May 2021
Pharmaceutical
The Russian government will use the mechanism of interventions in the domestic pharmaceutical market to tighten control of drug prices, according to recent statements by some senior state officials and local media, reports The Pharma Letter’s local correspondent. 25 May 2021
Pharmaceutical
The US Food and Drug Administration strictly prohibits the distribution of counterfeit, diverted, subpotent, substandard, adulterated, misbranded, and expired drugs that pose a serious threat to life. Nevertheless, such drugs continue to end up in circulation, compromising patient safety. 24 May 2021
Pharmaceutical
In support of Ehlers-Danlos Syndrome (EDS) Awareness Month, we explore the pharmacological landscape of this rare condition. 24 May 2021
Pharmaceutical
US pharma giant Merck & Co’s Russian MSD unit has revoked the registration certificate on its Belsomra (suvorexant) next-generation sleeping pill in Russia, due to the inability of the company to generate sales in the local market, reports The Pharma Letter’s local correspondent. 18 May 2021
Biotechnology
The Russian drugmaker R-Pharm will start the production of UK-based AstraZeneca’s COVID-19 vaccine at its facilities in Russia starting in June of the current year, according to recent statements by R-Pharm’s chief executive Vasily Ignatiev, as well as local media, reports the Pharma Letters local correspondent. 18 May 2021
Pharmaceutical
Global insulin producers are losing their positions in the Russian market, due to the active launch of generics by domestic suppliers, according to recent statements by Russian pharmaceutical analysts and local media, reports The Pharma Letter’s local correspondent. 11 May 2021
Pharmaceutical
The Russian drugmaker Nanolek plans to invest more than 5 billion roubles ($66 million) in the production of vaccines at its facilities within the next three years, according to recent statements by company and some local media, reports The Pharma Letter’s local correspondent. 5 May 2021
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Pharmaceutical laboratories, institutions, guilds and medical federations have taken on the task of designing programs to end health illiteracy in order to have informed, educated, knowledgeable and empowered communities where their health and wellbeing are concerned. 19 September 2024
Pharmaceutical
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
Generics
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
Pharmaceutical
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
Biotechnology
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
Generics
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Biotechnology
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
Generics
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
Pharmaceutical
Scientists from the Russian Institute of Immunology of the Federal Medical and Biological Agency (FMBA) say they have created the world's first allergy vaccine. 30 August 2024
Generics
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Pharmaceutical
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Generics
One of the largest pharmaceutical production facilities in the Russian North-West region will soon be built in the city of Pushkino by the local drugmaker Active Component enterprise, The Pharma Letter’s local correspondent reports. 14 August 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze